Followers | 17 |
Posts | 2913 |
Boards Moderated | 0 |
Alias Born | 03/22/2021 |
Friday, July 26, 2024 2:35:07 PM
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29 2024 - 8:30AM
Share On Facebook
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research agreement with Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
TransCode’s TTX platform will serve as a backbone for development of antigen-selective nucleic acid delivery vehicles for targeted cancer therapeutics. TransCode has developed and tested the TTX platform for the delivery of various nucleic acid therapeutics to cancer cells, including small interfering RNAs, antisense oligonucleotides, immunostimulatory oligonucleotides, mRNA, and genome-editing ribonucleoprotein complexes (CRISPR). TransCode’s lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial. As part of the collaboration, TransCode will combine its TTX delivery platform with Debiopharm’s proprietary technologies to generate constructs designed to provide targeted mRNA delivery to cancer cells. Under the agreement, these constructs will be tested both in cancer cells and in tumor-bearing animals.
Specializing in the manufacturing and development of oncology and antibiotic therapies, Debiopharm entered this research collaboration to test the development of new targeted nucleic acid delivery modalities. Debiopharm’s ongoing quest towards developing highly innovative drug delivery methods is based on the recognition that novel targeted medicines hold the potential to revolutionize cancer research and treatment by improving precision, efficacy, safety, and the overall therapeutic outcome for cancer patients. The company hopes that future advancements could usher in a new era of more effective and personalized cancer therapies.
Frédéric Lévy, Debiopharm’s Chief Scientific Officer, commented, “We believe that TransCode’s TTX platform has the potential to bring about significant advances in drug delivery for cancer because of its versatility in terms of the payloads it can be used to deliver, including not only a wide array of nucleic acids but also peptides and proteins.”
Zdravka Medarova, TransCode’s Chief Scientific Officer, added, “Debiopharm is a global player in the field of cancer therapeutics, known for the development of standard of care drugs for the treatment of various types of cancer. For TransCode, being able to collaborate with Debiopharm on an innovative project with the potential impact of targeted nucleic acid-based cancer therapeutics, represents a pivotal point for our company.”
Financial terms were not disclosed.
About TransCode Therapeuti
Recent RNAZ News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:02:19 PM
- TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 10:02:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:04:03 PM
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:45:28 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/26/2024 08:05:13 PM
- TransCode Therapeutics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 07/24/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 01:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 12:18:22 PM
- TransCode Therapeutics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 07/23/2024 02:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/22/2024 08:10:38 PM
- TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 07/22/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:16:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 12:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:06:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/10/2024 12:45:13 PM
- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements • GlobeNewswire Inc. • 06/10/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/07/2024 08:00:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:00:20 PM
- TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138 • GlobeNewswire Inc. • 05/29/2024 01:15:00 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 05/20/2024 08:00:16 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM